A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation

Table 1

Patient characteristics.

	Patient 1	Patient 2	Patient 3	Patient 4
Age at transformation, years	61	43	67	44
Gender	Male	Male	Female	Male
Rai stage	II	II	III	III
CLL-IPI	5	3	10	N/A
Cytogenetics	Trisomy 12, inversion 3, deletion 6q, deletion 11q, deletion 13q	Trisomy 12; +18; +19	Deletion 17p; +8q; +11q; deletion 13q	Normal
IGHV mutational status	Unmutated	Unmutated	Unmutated	N/A
Time to transformation	41 months	80 months	78 months	0 Months
MRD status of CLL at time of transformation	uMRD	+MRD with concurrent CLL	+MRD with concurrent CLL	+MRD with concurrent CLL
Prior CLL therapy	Ibrutinib + venetoclax	(1) Ibrutinib	(1) FCR	None
		(2) Acalabrutinib	(2) Ibrutinib
			(3) Acalabrutinib
Type I or II	Type II	Type I	Type I	Type I
EBV status	Positive	Positive	Negative	Negative
RS cell immunophenotype	CD30+; CD15+; MUM1+; PAX5 (dim); CD20-, CD5-	CD30+; CD15+; MUM1+; PAX5 (dim); CD20-, CD5-	CD30+; CD15+; MUM1+; PAX5 (dim); CD20-, CD5-	CD30+; CD15+; MUM1+; PAX5 (dim); CD20-, CD5-
Ann arbor stage	IVB	IIIB	IVB	IIIB
LDH (U/L)	248	189	276	302
Bone marrow involvement	Yes	No	No	No
>1, extranodal site	No	No	No	No
IPS score	2	1	3	3

CLL-IPI = international prognostic index for chronic lymphocytic leukemia; IGHV = immunoglobulin heavy chain variable; MRD = minimal residual disease; uMRD = undetectable minimal residual disease; CLL = chronic lymphocytic leukemia; EBV = Epstein–Barr virus; RS = Reed–Stenberg; LDH = lactate dehydrogenase; IPS = international prognostic score; FCR = fludarabine, cyclophosphamide, and rituximab.